I recall W3 said there was a gap @ 1.38. IMO there is no chance of that happening, zero. That would be to much of a correction from 2.29. I think the SP will stay around this range testing $2. Once we hear more news re the breast trial it’ll get a kick up again. I don’t see it ever hitting $18 Wombat777 fair value figure. The only driver to hit that height will be an early offer from big pharma....
RAC - Charts & Price Action, page-2766
-
- There are more pages in this discussion • 18,836 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
